Literature DB >> 12721948

Does the diagnosis of trachoma adequately identify ocular chlamydial infection in trachoma-endemic areas?

Mariko Bird1, Chandler R Dawson, Julius S Schachter, Yinghui Miao, Ahmed Shama, Ahmed Osman, Ahmad Bassem, Thomas M Lietman.   

Abstract

We evaluated the validity of clinically determined active trachoma as a surrogate for chlamydial eye infection in 1059 children from the Egyptian arm of the Azithromycin in the Control of Trachoma study. Participants were determined to be "clinically active" if they had >or=5 follicles or intense inflammatory infiltration on the tarsal conjunctiva. Conjunctival swabs were tested using ligase chain reaction (LCR) to detect chlamydial DNA. Of clinically active children aged 1-10 years, 31% did not have infection, as determined by LCR. Conversely, 31% of infected children were not clinically active; 78% of clinically active children aged 1-5 years were infected, versus 17% of those aged 11-15 years. The proportion of clinically active children who were infected decreased from 67% before treatment to 10% 14 months after mass azithromycin treatment. Clinically active trachoma is not always a reliable marker of infection, particularly in teenagers and after treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12721948     DOI: 10.1086/374743

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  31 in total

1.  Trachoma.

Authors:  J D Chidambaram; T M Lietman
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

2.  Trachoma, antibiotics and randomised controlled trials.

Authors:  B Shapiro; K Dickersin; T Lietman
Journal:  Br J Ophthalmol       Date:  2006-12       Impact factor: 4.638

3.  Active trachoma and ocular Chlamydia trachomatis infection in two Gambian regions: on course for elimination by 2020?

Authors:  Emma M Harding-Esch; Tansy Edwards; Ansumana Sillah; Isatou Sarr; Chrissy H Roberts; Paul Snell; Esther Aryee; Sandra Molina; Martin J Holland; David C W Mabey; Robin L Bailey
Journal:  PLoS Negl Trop Dis       Date:  2009-12-22

4.  Prevalence and risk factors for trachoma and ocular Chlamydia trachomatis infection in Niger.

Authors:  A Abdou; B Nassirou; B Kadri; F Moussa; B E Munoz; E Opong; S K West
Journal:  Br J Ophthalmol       Date:  2006-08-09       Impact factor: 4.638

5.  Detection by broad-range real-time PCR assay of Chlamydia species infecting human and animals.

Authors:  P Goldschmidt; H Rostane; M Sow; A Goépogui; L Batellier; C Chaumeil
Journal:  Br J Ophthalmol       Date:  2006-08-09       Impact factor: 4.638

6.  Clinical activity and polymerase chain reaction evidence of chlamydial infection after repeated mass antibiotic treatments for trachoma.

Authors:  Jeremy D Keenan; Takele Lakew; Wondu Alemayehu; Muluken Melese; Travis C Porco; Elizabeth Yi; Jenafir I House; Zhaoxia Zhou; Kathryn J Ray; Nisha R Acharya; John P Whitcher; Bruce D Gaynor; Thomas M Lietman
Journal:  Am J Trop Med Hyg       Date:  2010-03       Impact factor: 2.345

Review 7.  Diagnosis and assessment of trachoma.

Authors:  Anthony W Solomon; Rosanna W Peeling; Allen Foster; David C W Mabey
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

8.  The natural history of trachoma infection and disease in a Gambian cohort with frequent follow-up.

Authors:  Nicholas C Grassly; Michael E Ward; Shirley Ferris; David C Mabey; Robin L Bailey
Journal:  PLoS Negl Trop Dis       Date:  2008-12-02

Review 9.  Strategies to control trachoma.

Authors:  Anu A Mathew; Angus Turner; Hugh R Taylor
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546

10.  When can antibiotic treatments for trachoma be discontinued? Graduating communities in three African countries.

Authors:  Kathryn J Ray; Thomas M Lietman; Travis C Porco; Jeremy D Keenan; Robin L Bailey; Anthony W Solomon; Matthew J Burton; Emma Harding-Esch; Martin J Holland; David Mabey
Journal:  PLoS Negl Trop Dis       Date:  2009-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.